Eli Lilly Q1 Preview: GLP-1 Momentum Meets the Novo Test

$Eli Lilly(LLY)$   reports first-quarter 2026 earnings on April 30, and this print will be less about whether demand for GLP-1 drugs is strong. That part is already understood. The real question is whether Lilly can keep converting that demand into market-share gains, margin expansion, and confidence in its full-year guidance while Novo Nordisk pushes back with oral Wegovy and a broader obesity franchise. 

For Q1, consensus estimates vary by provider, but the Street is broadly looking for revenue around $17.6 billion to $17.8 billion and EPS around $7.3 to $7.5. 

The Obesity Market Is Still Growing, but the Debate Has Changed

The GLP-1 obesity market remains one of the most attractive growth pools in global pharma, but investor debate has shifted. A year ago, the key issue was whether supply could meet explosive demand. Now the focus is more nuanced: pricing, payer access, oral formulations, persistence, real-world adherence, and whether the total addressable market is being overestimated. Reuters recently reported that long-term obesity-drug sales forecasts have come down, with some 2030 estimates now around $100 billion and the prior $150 billion target pushed further out for some analysts. 

That matters for Lilly because the company is valued as a structural winner in obesity, not just as a cyclical pharma growth story. In 2025, Mounjaro generated $23.0 billion in full-year revenue, up 99%, while Zepbound generated $13.5 billion, up 175%. In Q4 alone, Mounjaro revenue rose 110% to $7.4 billion and Zepbound revenue rose 123% to $4.3 billion. The Q1 question is whether that growth engine is still accelerating, or whether volume strength is beginning to face more visible pricing and access headwinds.

Novo Nordisk Is Still the Benchmark Competitor

$Novo-Nordisk A/S(NVO)$   remains the key competitor because it still has scale, brand recognition, manufacturing depth, and a first-mover advantage in oral GLP-1 obesity. In 2025, Novo's obesity-care sales rose 31% at constant exchange rates to DKK 82.3 billion, and the company reported a 59.6% global branded volume share in obesity. That means Lilly is gaining ground, but Novo is not a weakened fringe player. It is still the incumbent Lilly must displace. 

The near-term battle is now moving into pills. Novo's oral Wegovy has an early lead, while Lilly's newly approved oral GLP-1, Foundayo, had a slower early prescription ramp. Reuters reported that Foundayo reached 3,707 U.S. prescriptions in its second week after launch, compared with 18,410 prescriptions for oral Wegovy in its second week after launch. That early gap does not decide the market, but it gives investors a fresh reason to ask whether Lilly's oral strategy can match the strength of its injectable franchise.

Watch 1: Mounjaro and Zepbound Momentum

The first and most important number is combined Mounjaro and Zepbound sales. Lilly's 2026 story still runs through tirzepatide. Investors should focus on three details: U.S. prescription growth, international uptake, and realized pricing. In Q4, Lilly said U.S. Mounjaro demand remained strong but was partially offset by lower realized prices, while Zepbound growth was also demand-driven but had similar pricing pressure. That dynamic is likely to remain central in Q1. If Lilly shows strong volume growth with manageable price erosion, the bull case remains intact. If the beat comes mainly from volume while price pressure worsens, the market may treat the result more cautiously.

Watch 2: Foundayo and the Oral GLP-1 Race

The second watch point is Foundayo. The drug is important not because it will transform Q1 revenue immediately, but because it could shape Lilly's next wave of obesity growth. Reuters reported that Foundayo is a once-daily oral GLP-1 that produced 12% to 15% body-weight reduction in clinical trials, and became available in early April after FDA approval. However, early prescription data have been modest versus Novo's oral Wegovy, and the FDA has also asked Lilly for additional post-marketing safety data related to potential liver injury. 

For fundamental investors, the key is not whether Foundayo beats oral Wegovy in week two. It is whether management can explain the launch cadence, payer access, pricing strategy, physician education, and safety-monitoring framework. A credible answer would help investors look past the early script gap. A vague answer could raise concerns that Lilly's oral obesity opportunity may be slower to scale than the market previously assumed.

Watch 3: Guidance, Margin, and Manufacturing Capacity

The third watch point is whether Lilly can maintain or raise 2026 guidance. The company's current outlook calls for $80 billion to $83 billion in revenue, a non-GAAP performance margin of 46.0% to 47.5%, and non-GAAP EPS of $33.50 to $35.00. Because Lilly is investing heavily in capacity, oral medicines, and pipeline expansion, investors will be watching whether gross margin and operating leverage remain clean as the company scales. 

Manufacturing remains an important part of the investment case. Lilly has announced new manufacturing investments, including a $6 billion active pharmaceutical ingredient facility in Alabama and a $3 billion oral medicine manufacturing facility in Europe. These investments support the long-term thesis, but they also keep the market focused on execution. The stronger the demand outlook, the more investors will ask whether supply, fill-finish, and oral capacity can keep up without pressuring margins. 

Options Market Signals

LLY options are pricing a high-stakes earnings event, not a routine pharma print. The chart shows total open interest of about 318.5K contracts and a put-call ratio of 1.04, suggesting positioning is close to balanced with a slight downside-hedging bias. Volatility is also elevated, with IV at 46.59%, above HV at 32.51%, and IV Percentile at 93%. Near-term options trackers are pricing roughly a 7% post-earnings move around Lilly's April 30 Q1 report. 

The signal is that traders are paying up for uncertainty around Lilly's GLP-1 story, especially Mounjaro, Zepbound, and the oral obesity-drug race against Novo Nordisk. With IV already rich, call spreads or put spreads may be more efficient than outright options. For volatility traders, the key question is whether earnings can drive a move larger than the roughly 7% already priced in, otherwise post-earnings IV crush becomes the main risk. 

Summary

Lilly enters Q1 earnings with one of the strongest growth profiles in large-cap pharma, but also with one of the clearest tests in the sector. Mounjaro and Zepbound remain the core growth engine, while Foundayo turns the Novo competition into a new oral GLP-1 battle. The most important takeaway for investors is whether Q1 confirms that Lilly can keep gaining share without sacrificing pricing, margins, or guidance credibility.

If Lilly delivers clean tirzepatide growth, credible Foundayo commentary, and stable 2026 guidance, the stock can continue to trade as the highest-quality obesity compounder. If the quarter shows early signs of pricing pressure, slower oral uptake, or margin strain, the market may start to separate "GLP-1 demand is strong" from "Lilly deserves an expanding multiple."

@TigerStars  @CaptainTiger  @TigerWire  @Daily_Discussion  @Tiger_chat  @Tiger_comments  @MillionaireTiger